1. Introduction {#sec1}
===============

Coronaviruses (CoVs) are enveloped RNA viruses covered with a non-segmented positive-sense RNA genome of 28 to 30 kb, known since the mid-1960s \[[@bib1]\]. These viruses can infect a variety of hosts and can cause different respiratory, enteric, liver, and systemic diseases \[[@bib1], [@bib2]\]. CoVs have the potential to transmit among animals and humans \[[@bib3], [@bib4]\], that is evident from previous CoVs outbreaks. The Severe Acute Respiratory Syndrome (SARS) surfaced in 2002/2003 and resulted in 800 deaths \[[@bib5]\]. Soon after, the rise of this new viral infection, several new CoVs were uncovered \[[@bib6]\]. In 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) was identified with potential of human-to-human transmission \[[@bib7], [@bib8]\]. The mortality rate of SARS-CoV and MERS-CoV was estimated to be around 15% for SARS-CoV \[[@bib9]\] and 35% for MERS-CoV \[[@bib10]\]. The currently emerged SARS-CoV-2, spread globally and turned into pandemic of life threatening coronavirus disease-2019 (COVID-19) \[[@bib11]\]. To date, various potential SARS-CoV-2 drug targets have been reported, and various efforts have been made to identify potential therapeutics as presented in recent reviews \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15]\].

Belongs to beta-CoVs, SARS-CoV-2 based on 800-kDa polypeptide, which cleaved into structural and non-structural proteins upon translation \[[@bib16], [@bib17]\]. 3-chymotrypsin- like protease (3CL^pro^) as well as papain-like protease (PL^pro^) are active partners in mediating this proteolytic processing. CoVs PL^pro^ grouped in the peptidase clan CA (family C16). The active site of PL^pro^ consists a typical catalytic triad, comprised of Cys111--His272--Asp286 residues. CoVs PL^pro^ is extensively studied, well-aligned, functional, and situated at the border of the thumb and palm sub-domains \[[@bib18]\]. PL^pro^ performs its proteolytic functions through its catalytic cysteine-protease cycle, in which Cys111 functions as a nucleophile, His272 acts as a general acid/base and Asp286 is linked with the histidine assisting it to align and help deprotonation of Cys111 \[[@bib19]\]. CoVs 3CL^pro^ and PL^pro^ mainly process the viral polyprotein. However, PL^pro^ has an extra role of extracting ISG15 and ubiquitin from the proteins of host-cell to help CoVs in the dodging of host-innate immune responses \[[@bib19], [@bib20]\]. The C-terminal of ubiquitin molecule was suggested to accommodate a cleft in close proximity to the functional catalytic triad which consisted of the conserved ubiquitin-specific protease residue, Asp 164 and two hydrophobic subsites S3 and S4. Targeting this pocket is preferable for the development of non-covalent SARS-CoV agents as it could allosterically block the active site by inducing loop closure \[[@bib21]\]. Therefore, PL^pro^ is a significant target for anti-CoVs drug designing \[[@bib22]\]. PL^pro^ based antiviral drugs may not only inhibit the CoVs replication cycle, they may also have an advantage in impeding the dysregulation of signalling cascades in CoVs infected cells that further lead to the death of un-infected neighbouring cells \[[@bib19]\].

Up to date, no clinically approved drug or vaccine available to protect against recent COVID-19 \[[@bib23], [@bib24]\]. For treating COVID-19 pneumonia, health officials are currently testing and evaluating existing anti-pneumonia treatments. Existing antivirals, including protease inhibitors (indinavir, saquinavir, and lopinavir/ritonavir) as well as RNA polymerase inhibitors, including remdesivir \[[@bib25], [@bib26], [@bib27]\] are being tested against SARS-CoV-2. Recently, the *in vitro* antiviral competence analyses of few FDA-approved as well as experimental drugs against clinical isolates of SARS-CoV-2, such as chloroquine and remdesivir showed promising results \[[@bib26]\]. However, to tackle the current COVID-19 pandemic, the development of wide-spectrum inhibitors against CoVs is a crucial strategy.

In recent years, the use of computational approaches for the discovery of small molecules has achieved importance in drug development \[[@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33]\]. Among various approaches, molecular docking has been extensively used for investigating the binding interactions of small molecules with the active sites of the target protein \[[@bib34], [@bib35], [@bib36], [@bib37], [@bib38]\]. In antiviral drug discovery, hierarchical virtual screening approaches already identified promising antiviral compounds against a broad range of viruses including influenza \[[@bib39]\], Ebola \[[@bib40], [@bib41], [@bib42]\], Dengue \[[@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48]\], Zika Virus \[[@bib48], [@bib49], [@bib50]\] and recently against CoVs \[[@bib22], [@bib51], [@bib52], [@bib53]\], while others displayed the significance of MD simulations in search for possible anti-viral \[[@bib44], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60], [@bib61]\] and investigated drug resistance mechanisms \[[@bib54], [@bib58], [@bib62], [@bib63], [@bib64]\]. PL^pro^ is a highly conserved protease across CoVs \[[@bib65]\] and considered as potential target for SARS-CoV inhibitors with broad-spectrum antiviral activity \[[@bib19]\]. In this contribution, a combined virtual screening approach and all-atom MD simulations were employed to investigate potential pan-PL^pro^ inhibitors that could be further developed into broad-spectrum anti-COVID-19 drugs.

2. Materials and methods {#sec2}
========================

2.1. Proteins sequence and structure alignment {#sec2.1}
----------------------------------------------

The functional evolutionary conserved residues of SARS-CoV, SARS-CoV-2 and MERS-CoV were recognized through sequence and structure alignments that could provide a structural motif for inhibitor design towards the discovery of pan-PL^pro^ based broad spectrum anti-COVID-19 hits. Sequence and 3D structures of SARS-CoV-2 PL^pro^ (PDB: 6W9C), SARS-CoV PL^pro^ (PDB: 3MJ5), and MERS-CoV PL^pro^ (PDB: 4R3D) were retrieved from PDB \[[@bib66]\]. Clustal Omega \[[@bib67]\] was used to align the PL^pro^ sequences. Structure alignment analysis was performed using PyMOL 1.3. tool \[[@bib68]\].

2.2. Chemical libraries preparation {#sec2.2}
-----------------------------------

The Asinex protease inhibitor library composed of 6968 compounds in three-dimensional (3D) representation and structural data format (SDF) was downloaded from the Asinex platform (<https://www.asinex.com/protease/>). The compounds were imported, and energy minimized using MMFF94 force field implemented in Open Babel \[[@bib69]\]. Then compounds were prepared for screening using Autodock Tools \[[@bib70]\] by adding the polar hydrogens and computing the gasteiger charges. All the optimized compounds were then saved as PDBQT files format for further molecular docking studies.

2.3. Structure-based virtual screening and molecular docking {#sec2.3}
------------------------------------------------------------

The x-ray structure of SARS-CoV-2 PL^pro^ in a resolution of 2.7 Å (PDB: 6W9C) was used for the docking purpose. Initially, the co-crystalized inhibitors and unwanted water molecules were removed by the Discovery studio visualizer \[[@bib71]\]. The protein structure was prepared from PDB files into PDBQT using Autodock Tools. The polar-hydrogen atoms were included, and gasteiger charges were processed before docking. The structure-based virtual screening was carried out using Autodock-vina in PyRx 0.8 virtual screening tool \[[@bib72]\]. Due to the high degree of sequence identity, the structure of SARS-CoV PL^pro^ (PDB: 3MJ5) bound to GRL‐0667S, a non-covalent inhibitor, was used to determine the target site within SARS-CoV-2 PL^pro^. The docking target site was determined by 3D structural alignment of SARS-CoV-2 PL^pro^ (PDB: 6W9C) with SARS-CoV PL^pro^ (PDB: 3MJ5). Hence, the grid box was generated by confining the essential residues lining this binding cavity. The three top hits were then re-docked individually using Autodock-Vina 1.1.2 to predict their binding modes and mechanism of interactions. The docking parameters were initially validated by redocking of native ligand GRL‐0667S into the active site of SARS-CoV PL^pro^ (PDB: 3MJ5). Also, these hits were docked against SARS-CoV PL^pro^ (PDB: 3MJ5) and MERS-CoV PL^pro^ (PDB: 4R3D) using the same method. Discovery studio Visualizer 4.5 \[[@bib73]\] and PyMOL 1.3 \[[@bib68]\] programs were used for data and interaction analyses.

2.4. *In silico* drug-likeness analysis and ADMET profiling {#sec2.4}
-----------------------------------------------------------

The available bioinformatics tool SwissADME (available online: <http://www.swissadme.ch/index.php>) \[[@bib74]\] was used for finding the drug-likeness properties. Based on the Lipinski\'s rule of five \[[@bib75]\], the properties that have been considered were molecular mass (MW), H-bond donor (HBD), H-bond acceptor (HBA), lipophilicity (log P), aqueous solubility and rotatable bonds (QP log S). PreADMET (<https://preadmet.bmdrc.kr/>) and pkCSM (<http://biosig.unimelb.edu.au/pkcsm/>) \[[@bib76]\] servers were used to determine the ADMET (absorption, distribution, metabolism, excretion, and toxicity) parameters of candidate compounds.

2.5. Molecular dynamics (MD) simulation {#sec2.5}
---------------------------------------

All atoms MD simulation of SARS-CoV-2 PL^pro^-inhibitor complexes and apo-protein were performed at 50 ns using GROMACS 2018 package \[[@bib77]\]. The simulation was carried out using previously reported protocol \[[@bib53], [@bib78]\]. Briefly, Chimera UCSF Chimera 1.14 was used to prepare the crystal structure of apo-SARS-CoV-2 PL^pro^ and in complex with the top pose of docked-compounds for MD simulation \[[@bib79]\]. The topology and parameters of compounds were obtained using SwissParam (<http://www.swissparam.ch/>). The simulation was conducted by applying OPLS-AA/L force-field to the systems in a 3D cubic box of TIP3P model of water molecules. Next, the simulated systems were equilibrated, and energy minimized by steepest-decent algorithm, followed by equilibration using Canonical (NVT) as well as (Isothermal/isobaric) NPT ensembles. The MD simulation were analyzed for the root-mean square deviation (RMSD), root-mean square fluctuations (RMSF), potential binding energy, a radius of gyration (Rg), H-bond interaction analysis, solvent accessible surface area (SASA) and principal component analysis (PCA).

2.6. Binding free-energy calculations {#sec2.6}
-------------------------------------

The binding free-energies (ΔG~bind~) of the candidates were computed using the MM-PBSA algorithm \[[@bib80]\], employed in AMBER 18, as previously described \[[@bib81], [@bib82]\]. The molecular mechanics (MM) force fields were utilized to calculate the energy contributions of the receptor, ligand, and complex in a gaseous phase. The total binding free-energy (ΔG~total~) is determined as a total energy released from the ligand/protein complex which is contributed by molecular mechanics binding energy (ΔE~MM~) and solvation free energy (ΔG~sol~) using the following equations:

In which, ΔE~MM~ is divided into internal energy (ΔE~int~), electrostatic energy (ΔE~ele~), and van der Waals energy (ΔE~vdw~), and the polar (ΔG~p~) and non-polar (ΔG~np~) energy components contributed to total solvation free energy (ΔG~sol~). ΔG~bind~ is the free energy of binding evaluated after entropic calculations (-TΔS), for both MM-GBSA and MM-PBSA methods. In order to estimate the decisive role of interacting residues towards ligand\'s binding, per-residue energy decomposition analysis was performed using the MM-GBSA method, and binding energy were calculated as ΔG~residue~ using the following equation.

The ΔG~residue~ includes the total energy obtained from sidechain and backbone energy decomposition. These methods have been well demonstrated in binding free energy calculations \[[@bib83]\] for antiviral inhibitors \[[@bib84], [@bib85]\].

3. Results and discussion {#sec3}
=========================

3.1. Sequence, structural and functional analysis of PL^pro^ for conserveness among coronaviruses {#sec3.1}
-------------------------------------------------------------------------------------------------

The sequence alignment of SARS-CoV-2 PL^pro^ protein sequence displayed an identity of 82.80% and only 30.00% with SARS-CoV PL^pro^ and MERS-CoV PL^pro^, respectively ([Fig. 1](#fig1){ref-type="fig"} ). However, the sequence alignment revealed that PL^pro^ crucial catalytic triad residues of CoVs PL^pro^ are well conserved amongst SARS-CoV-2 (Cys111-His272-Asp286), SARS-CoV (Cys112-His273-Asp287) and MERS-CoV (Cys112-His275-Asp294).Fig. 1Multiple sequence alignments of SARS-CoV-2 PL^pro^ with SRAS-CoV PL^pro^ and MERS-CoV PL^pro^. The conserved catalytic triad residues (Cys111-His272-Asp286) within SARS-CoV-2, (Cys112-His273-Asp287) within SARS-CoV and (Cys112-His275-Asp294) within MERS-CoV are highlighted with red color arrows.Fig. 1

In consistent with this, the structural alignment/superposition of all three human CoVs PL^pro^ revealed that the PL^pro^ of SARS-CoV-2 ([Fig. 2](#fig2){ref-type="fig"} A) adapts the same folding pattern as same as the PL^pro^ of SARS-CoV and MERS-CoV ([Fig. 2](#fig2){ref-type="fig"}B). Interestingly, the functionally well-conserved catalytic triad residues within the catalytic pockets of PL^pro^ among SARS-CoV-2, SARS-CoV, and MERS-CoV, present at the identical place in the catalytic sites with RMSD 1.342 Å as presented in [Fig. 2](#fig2){ref-type="fig"}B and 2C. To determine the targetable binding site within the SARS-CoV-2 PL^pro^, the crystal structure of SARS-CoV PL^pro^ in complex with a potent non-covalent inhibitor, GRL‐0667S, was used for structural alignment. The binding site appeared as an allosteric site close to the active catalytic site ([Fig. 2](#fig2){ref-type="fig"}B and 2D).Fig. 2(**A**) The 3D structures of SARS-CoV-2 PL^pro^ enzymes. The catalytic triad residues Cys111-His272-Asp286 were shown green sticks. (**B**) The overlapping of the 3D structures of PL^pro^ enzymes of SARS-CoV-2 (green) (PDB: 6W9C), SRAR-CoV (yellow) (PDB: 3MJ5) and MERS-CoV (purple) (PDB: 4R3D). The conserved catalytic triad residues with each structure were shown in sticks. GRL‐0667S within the binding site of SRAS-CoV PL^pro^ was shown in orange spheres. (**C**) The overlapping of the catalytic triad residues of PL^pro^ within the active sites of SARS-CoV-2 (green sticks), SRAR-CoV (cyan sticks), and MERS-CoV (pink sticks). (**D**) Close view to the targetable binding pocket within PL^pro^ enzyme based on the binding mode of GRL‐0667S with SARS-CoV PL^pro^.Fig. 2

3.2. Virtual screening of protease inhibitor library {#sec3.2}
----------------------------------------------------

Integrated computational methods comprising virtual high throughput screening, molecular docking, and MD simulation are a significant approach for the exploration of potential inhibitors against a target protein \[[@bib22], [@bib28], [@bib78], [@bib86]\]. In order to find out potential pan-PL^pro^ based anti-SARS-CoV-2 inhibitors, the structure-based screening was carried out against a virtual library of ∼7000 protease inhibitors. By applying a docking score cutoff of lower than -8.5 kcal/mol, three potential hits ([Fig. 3](#fig3){ref-type="fig"} ) were selected with maximum scores, which were found interacted well with the active site residues. These include ADM_13083841 ((S)-4-(2-(2-(5-methyl-7-oxo-6,7-dihydropyrazolo\[1,5-a\]pyrimidin-2-yl)pyrrolidin-1-yl)-2-oxoethyl)phthalazin-1(2H)-one), AEM_16392818LMG_15521745 (N-(2-(3H-pyrazol-4-yl)ethyl)-4-((3-(2-fluorophenyl)isoxazol-5-yl)methyl)tetrahydro-2H-pyran-4-carboxamide) and SYN_15517940 ((R)-2-methyl-6-(((1R,5R)-8-oxo-1,5,6,8-tetrahydro-2H-1,5-methanopyrido\[1,2-a\]\[[@bib1],[@bib5]\]diazocin-3(4H)-yl)sulfonyl)-2H-benzo\[b\]\[[@bib1],[@bib4]\]oxazin-3(4H)-one) with binding energy score of -8.9, -8.7, -8.7 kcal/mol, respectively, and considered as potential inhibitors of SARS-CoV-2 PL^pro^ ([Table 1](#tbl1){ref-type="table"} ). These three hit compounds were used to further evaluate the physiochemical and ADMET properties.Fig. 3Chemical structures of screened hits; (**A**) ADM_13083841, (**B**) LMG_1552174, and (**C**) SYN_15517940.Fig. 3Table 1Properties profile of candidate compounds.Table 1Name (ID)**Binding score (kcal/mol)**Hydrogen bond interactionHydrophobic interactionADM_13083841-8.9Lys157, Tyr264,Thr301Leu162, Met208LMG_15521745-8.7Lys157, Tyr264,Thr301Leu162, Pro248SYN_15517940-8.7Arg166,Thr264, Thr301Leu162, Met208, Pro248

3.3. Analysis of screened inhibitor interaction {#sec3.3}
-----------------------------------------------

In order to understand the binding mode and mechanism of interaction of these compounds with SARS-CoV-2 PL^pro^, an unbiased flexible docking of these compounds into the active site of the SARS-CoV-2 PL^pro^ enzyme was performed. The docking and scoring functions were validated before the docking was carried out. Since SARS-CoV and SARS-CoV-2 shared significant sequence similarity and similar 3D structure, the validation was achieved by docking the GRL‐0667S, a potent SARS CoV PL^pro^ inhibitor with an IC~50~ value of 0.32 ± 0.01 μM, into the same site within SARS-CoV-2 \[[@bib87]\]. The latter approach was made to evaluate the ability of the docking protocol to predict the biologically active conformation. Moreover, as shown in [Fig. 4](#fig4){ref-type="fig"} , both the docked conformation within SARS-CoV-2 and co-crystal ligand within SARS-CoV adapted similar binding mode within the target site validating the robustness of the docking protocol.Fig. 4Validation of the docking protocol. (**A**) Ribbon representation for superimposition of docked GRL‐0667S (cyan) into SARS-CoV-2 PL^pro^ (green) (PDB: 6W9C), and co-crystalized structure (orange) of GRL‐0667S within the active site of SARS CoV PL^pro^ (yellow) (PDB: 3MJ5). (**B**) Superimposition of co-crystallized (orange) and best-docked pose (cyan) of inhibitor GRL-0667S in the active site of SARS-CoV-2 PL^pro^ (PDB ID: 6W9C, green molecular surface).Fig. 4

Flexible docking revealed that the three compounds adopt the same binding mode within the binding pocket and interacted through H-bonds as shown in [Fig. 5](#fig5){ref-type="fig"} . Among the conserved H-bonds interactions, the terminal pyrimidin-4-one of ADM_13083841, central oxane moiety of LMG_15521745 and terminal benzoxazines moiety of SYN_15517940 established one H-bond each with the side chain oxygen atom of Thr301. Second conserved H-bond was established between the side chain oxygen of Tyr264 and the central pyrrolidine moiety of ADM_13083841, oxazole moiety of LMG_15521745, and sulfonamide moiety of SYN_15517940. Apart from these, ADM_13083841 and LMG_15521745 also established conserved interaction with the side-chain nitrogen (N) of Lys157, while SYN_15517940 established H-bond with the side-chain N of Arg166. Moreover, these compounds also formed conserved network of hydrophobic interactions with the surrounding residues, including Leu162, Asp164, Met208, Pro247, Pro248, and Tyr268. The molecular interaction analyses were found in agreement with the co-crystallized inhibitors of SARS-CoV-PL^pro^ (PDB ID: 3E9S and 3MJ5) \[[@bib87]\] ([Table 1](#tbl1){ref-type="table"}).Fig. 5Binding modes and molecular interactions of screened compounds with SARS-CoV-2 PL^pro^ (PDB: 6W9C). (**A**) Surface representation of the binding mode of GRL‐0667S (cyan), ADM_13083841 (white), LMG_1552174 (pink) and SYN_15517940 (yellow) to SARS-CoV-2 PL^pro^ (green). (**B**) The mechanism of molecular interactions of (**a**) ADM_13083841 (white), (**b**) LMG_1552174 (pink) and (**c**) SYN_15517940 (yellow) to SARS-CoV-2 PL^pro^ (green).Fig. 5

3.4. ADMET screening and drug-ability results {#sec3.4}
---------------------------------------------

ADMET-based drug scan tool at the SwissADME server \[[@bib74]\] was used to evaluate the drug-likeness of the proposed SARS-CoV-2 PL^pro^ inhibitors. ADM_13083841 (C21H20N6O3) is a phthalazinone derivative with the Log P value of 2.04 and molecular weight of 404.42 g/mol. The compound has six hydrogen-bond acceptor (HBA) and one hydrogen-bond donor (HBD) atoms. Another oxaazole based compound selected from the docked molecules is LMG_15521745 (C21H23FN4O3) with the LogP value of 3.02 and molecular weight of 398.43 g/mol. It contains seven HBA atoms and one HBD. SYN_15517940 (C20H21N3O5S) has a log P value of 2.30 and a molecular weight of 415.46g/mol, together with six HBA atoms and one HBD. ([Table 2](#tbl2){ref-type="table"} ).Table 2Drug-likeness properties of identified compounds.Table 2Name**Mwt (g/mol)**HBDHBALog PRBLog SADM_13083841404.42162.044-2.84 SolubleLMG_15521745398.43173.028-3.54 SolubleSYN_15517940415.46162.302-2.62 Soluble

For further validation of the drug likeliness capability of target compounds, all these compounds were subjected to the PreADMET and pkCSM server, that have five main parameters (absorption, distribution, metabolism, excretion, and toxicity) to assess them. These five parameters were then assessed according to the number of thresholds. All the three compounds successfully passed the criteria of drug-ability ([Table 3](#tbl3){ref-type="table"} ).Table 3ADMET Profiling for absorption, metabolism and toxicity parameters of identified compounds.Table 3ModelADM_13083841LMG_15521745SYN_15517940**A. Absorption and distribution**Blood-brain barrierNoNoNoHuman intestinal absorptionHighHighHighCaco-2 permeabilityYesYesNoP-glycoprotein inhibitorSubstrate/InhibitorNon substrate/InhibitorNon substrate/Non inhibitorOrganic cation transporter 2 (OTC2)Non inhibitorNon inhibitorNon inhibitor**B. Metabolism**CYP450 2C9Non inhibitorInhibitorNon inhibitorCYP450 2D6Non substrate/Non inhibitorNon substrate/non inhibitorNon substrate/Non inhibitorCYP450 3A4Substrate/Non inhibitorSubstrate/InhibitorSubstrate/Non inhibitorCYP450 1A2Non inhibitorNon inhibitorNon inhibitorCYP450 2C19InhibitorInhibitorNon inhibitor**C. Toxicity**Acute algae toxicity0.02642730.06215670.158197Ames testMutagenMutagenNon-mutagenCarcinogenicity (Mouse)NegativeNegativeNegativeCarcinogenicity (Rat)NegativeNegativeNegativeAcute daphina toxicity0.125990.3643290.661198in vitro hERG inhibitionHigh riskHigh riskMedium RiskAcute fish toxicity (medaka)0.03549280.2273240.836634Acute fish toxicity (minnow)0.05444610.2487980.94807Ames TA100 (+S9)PositiveNegativeNegativeAmes TA100 (-S9)NegativeNegativeNegativeAmes TA1535 (+S9)NegativePositiveNegativeAmes TA1535 (-S9)NegativePositiveNegative

3.5. Molecular dynamics (MD) simulation {#sec3.5}
---------------------------------------

MD simulation is wieldy used computational methods to analyze the dynamic behavior and stability of a ligand/protein complex under different conditions \[[@bib30], [@bib53], [@bib88], [@bib89]\]. All atoms MD simulations were carried out on the initial conformation of the hit compounds-PL^pro^ complexes obtained after the docking in the solvated states at 50 ns.

### 3.5.1. Root-mean square deviation (RMSD), Root mean square fluctuation (RMSF) and Potential binding energy {#sec3.5.1}

The RMSD computes the direct changes in the atoms of superimposed proteins and an acceptable approach to assess the stability of protein/ligand complexes \[[@bib90], [@bib91], [@bib92], [@bib93]\]. The RMSD values of the Cα-backbone atoms of SARS-CoV-2 PL^pro^ in complex to the three PL^pro^ potential inhibitors were calculated with respect to the initial structure and compared with apo-protein in an unbound form. The RMSD values steadily increased in the start and remained converged throughout the simulation period, especially for ADM_13083841 and LMG_15521745 complexes. Similarly, the RMSD values of apo-protein reached equilibrium after an initial increase within the first 5ns and converged between 0.12 -- 0.3 nm throughout the simulation course. The average RMSD calculations for the last 45 ns for apo-protein, ADM_13083841, LMG_15521745, and SYN_15517940 complexes were 0.18 ±0.03, 0.18±0.03, 0.19 ±0.04 and 0.18 ±0.03 nm, respectively ([Fig. 6](#fig6){ref-type="fig"} A).Fig. 6(**A**) The root mean square deviation (RMSD) of C--Cα--N backbone vs. simulation time for solvated SARS-CoV-2 PL^pro^ in apo-state and in complex with the three candidate compounds over the time of 50 ns MD simulation. (**B**) The root mean square fluctuation (RMSF) of SARS-CoV-2 PL^pro^ in apo-state and in complex with the three candidate compounds. (**C**) The potential energy for SARS-CoV-2 PL^pro^ in apo-state and in complex with the candidate compounds over the time of 50 ns MD simulation.Fig. 6

The RMSF measures the local protein flexibility and proved to be an excellent parameter to investigate the protein\'s residual flexibility over the simulation period \[[@bib90], [@bib92]\]. The time average of protein backbone RMSF values of the 315 amino acids of SARS-CoV-2 PL^pro^ protein with and without the three candidate compounds was calculated over the 50 ns simulation period. Normal fluctuations in the constituent residues of SARS-CoV-2 PL^pro^ were observed for apo-protein and all three complexes, PL^pro^- ADM_13083841, PL^pro^- LMG_15521745and PL^pro^- SYN_15517940 and were plotted to compare the residual flexibility. As shown in [Fig. 6](#fig6){ref-type="fig"}B, major fluctuations were observed mainly in the loop regions (residue no. 185 -- 200 and 220 - 230), located away from the binding pocket. The average RMSF values were calculated as 0.09 ±0.05, 0.11 ±0.05, 0.11 ±0.06 and 0.09 ±0.04 nm for apo-protein, ADM_13083841, LMG_15521745 and SYN_15517940, respectively.

Furthermore, the potential energy over the simulation time for the three complexes and apo-protein was calculated. The results indicated that the three complexes remained in a stable pattern throughout the 50 ns simulations, as shown in [Fig. 6](#fig6){ref-type="fig"}C. This RMSD, RMSF, potential energy MD simulation results confirmed the stability of all selected compounds at the catalytic-site of SARS-CoV-2 PL^pro^.

### 3.5.2. Radius of gyration (Rg), Hydrogen bond interaction and solvent accessible surface area (SASA) analysis {#sec3.5.2}

The Rg is an evaluating parameter for the behavior and stability of the biological systems during the MD trajectories by measuring the compactness of biomacromolecules' structures \[[@bib94], [@bib95]\]. The Rg can also be used as an indicator of whether the complex will maintain folded conformation after the MD simulation. The Rg values of the three complexes and apo-protein were stabilized after the initial increase at 5 ns, supporting the RMSD results that systems have reached the equilibrium state ([Fig. 7](#fig7){ref-type="fig"} A). The average Rg values for the three complexes and apo-protein remained relatively consistent for the last 45 ns indicating a stably folded structure with an average value of 2.32 ±0.01, 2.32 ±0.02, 2.32 ±0.02 and 2.31 ±0.01 nm for apo-protein, ADM_13083841, LMG_15521745, and SYN_15517940, respectively.Fig. 7(**A**) The radius of gyration (Rg) of SARS-CoV-2 PL^pro^ in apo-state and in complex with the three candidate compounds during 50 ns MD simulation. (**B**) Plot of number of hydrogen bond within the SARS-CoV-2 PL^pro^ in complex with the three candidate compounds during 50ns MD simulation. (**C**) Plot of solvent accessible surface area (SASA) of SARS-CoV-2 PL^pro^ in apo-state and in complex with the three candidate compounds over the time of 50 ns MD simulation.Fig. 7

Hydrogen bonds play a crucial role as stabilizing forces for a ligand-protein complex \[[@bib90], [@bib91], [@bib92]\]. The total number of hydrogen bonds formed between the three candidate compounds and SARS-CoV-2 PL^pro^ is showing in [Fig. 7](#fig7){ref-type="fig"}B. All candidate compounds can make up to four stable hydrogen bonds with SARS-CoV-2 PL^pro^ throughout the simulation period supporting the docking results. These bonding parameters represented that all candidate compounds may bind effectively and tightly to the SARS-CoV-2 PL^pro^.

The solvent Accessible Surface Area (SASA) is a tool to measure the water accessible proportion of the biomolecule surface \[[@bib96]\]. The calculation of SASA value is a useful tool to predict the degree of the conformational changes which resulted due to complex interaction. The calculated average SASA value for the last 45 ns simulation time was 165.27 ±1.22, 164.78 ±1.21, 165.18 ±1.18, and 165.51 ±1.27 nm^2^, respectively ([Fig. 7](#fig7){ref-type="fig"}C). These results suggested there were no observed changes in the accessibility area of all three systems over the 50 ns simulation time. Thus, in terms of SASA analysis, the relative stability of our protein-ligand complexes has been concluded.

### 3.5.3. Principle component analysis (PCA) {#sec3.5.3}

The PCA analysis was performed to identify conformational changes that accompany the ligands binding within different protein/ligand complexes. In the current study, the first two principal components (PC1 and PC2) were selected for predicting the protein motions. The projection of two eigenvectors for apo-protein as well as all three complexes; PL^pro^- ADM_13083841, PL^pro^- LMG_15521745, and PL^pro^- SYN_15517940 are shown ([Fig. 8](#fig8){ref-type="fig"} ). Generally, the complex that occupies a more phase-space with a non-stable cluster and complex that occupies less phase-space with a stable cluster represented a less stable complex and a more stable complex, respectively. From the graphs, the apo-protein, as well as the three complexes, occupied less phase-space. The clusters shifting were from -4 to 5nm in case of apo-protein, -8 to 6 nm in case of ADM_13083841. Whereas, it was from -6 to 6 and -4 to 4 in case of LMG_15521745 and SYN_15517940, respectively. With respect to apo-protein values, all complexes showed a very stable complex.Fig. 8Two-dimensional principle component analysis (PCA) projections of trajectories obtained from 50 ns MD simulations.Fig. 8

3.6. Predicted binding free energy calculations {#sec3.6}
-----------------------------------------------

The MM/GBSA and MM/PBSA are both end-point methods and represented more physically meaningful information than docking scoring functions. These methods have been extensively utilized in the identification of potential antiviral inhibitors \[[@bib83], [@bib84], [@bib97], [@bib98]\]. The absolute energy of binding (ΔG~bind~) of all three hit compounds together with co-crystallized PL^pro^ inhibitor, GRL‐0667S \[[@bib87]\] were predicted through mechanics/Poisson--Boltzmann (generalized born) surface area (MM/PB(GB)SA) method on 50 snapshots extracted from the last 20 ns of the simulation period. It is important to note that we also incorporated entropic contributions (-TΔS) in ligand binding, which are computationally expensive in the MMPBSA method and give better accuracy \[[@bib99]\]. Moreover, entropy effects play an essential role in protein-ligand interactions \[[@bib100]\]. The calculations are tabulated in [Table 4](#tbl4){ref-type="table"} .Table 4ΔG~bind~ Values of ADM_13083841, LMG_1552174 and SYN_15517940 in complex with SARS-CoV-2 PL^pro^ calculated by the MM/PB(GB)SA method. The co-crystalized complex GRL‐0667S/SARS-CoV-2 PL^pro^ (PDB: 3MJ5) was used as positive control.Table 4Energy componentADM_13083841LMG_1552174SYN_15517940GRL‐0667S**MM (Gas term)ΔE**~**vdw**~-46.12-41.3-39.88-43.7**ΔE**~**ele**~-14.1-16.24-15.3-12.39**ΔE**~**MM**~-60.22-57.54-55.18-56.09**(-)TΔS**24.321.2221.920.91**PBSA (solvation term)ΔG**~**p(PBSA)**~35.937.2631.2734.76**ΔG**~**np(PBSA)**~-5.07-5.11-5.1-5.39**ΔG**~**sol(PBSA)**~30.8332.1526.1729.37**GBSA (solvation term)ΔG**~**p(GBSA)**~29.4531.3727.2331.38**ΔG**~**np(GBSA)**~-5.42-5.89-6.91-6.02**ΔG**~**sol(GBSA)**~24.0325.4820.3225.36**Binding free energyΔG**~**bind(MM/PBSA)**~-5.09-4.17-7.11-5.81**ΔG**~**bind(MM/GBSA)**~-11.89-10.84-12.96-9.82[^2]

According to the MM/PB(GB)SA calculations, van der Waals (ΔE~vdW~) interaction was the main driving force in complex stabilization with ADM_13083841 (ΔE~vdW~ = -46.12 kcal/mol)**,** LMG_15521745 (ΔE~vdW~ = -41.3 kcal/mol) and SYN_15517940 (ΔE~vdW~ = -39.88 kcal/mol) and was about 1-2 fold stronger than electrostatic attraction energy (ΔE~ele~) which were predicted to be -14.1, -16.24, and 15.3 kcal/mol, respectively. Therefore, it was found that compounds interacted mainly through van der Waals interactions and these findings are in agreement with the co-crystalized GRL‐0667S (ΔE~vdW~ = -43.7 and ΔE~MM~ = -12.39) \[[@bib87]\]. Together with the solvation effect in ADM_13083841 (ΔG~sol(PBSA)~ = 30.83; ΔG~sol(GBSA)~ = 24.03 kcal/mol), LMG_15521745 (ΔG~sol(PBSA)~ = 32.15; ΔG~sol(GBSA)~ = 25.48 kcal/mol) and SYN_15517940 (ΔG~sol(PBSA)~ = 26.17; ΔG~sol(GBSA)~ = 20.32 kcal/mol) complexed with SARS-COV-2 PL^pro^ and incorporation of entropic terms, the absolute ΔG~bind~ was account for -5.09 (ADM_13083841), -4.17 (LMG_15521745) and -7.11 kcal/mol (SYN_15517940) as per MM-PBSA (ΔG~bind(MM/PBSA)~) approach and values of 11.89 (ADM_13083841), -10.84 (LMG_15521745) and -12.96 kcal/mol (SYN_15517940) were taken from the MM-PBSA (ΔG~bind(MM/PBSA)~) approach. The obtained ΔG~bind~ values of all three compounds were in agreement with the co-crystalized GRL‐0667S which revealed a relatively similar value by MM/PBSA (-5.81 kcal/mol) and MM/GBSA (-9.82 kcal/mol) methods.

### 3.6.1. Per-residue decomposition analysis {#sec3.6.1}

In order to evaluate the binding role of key interacting residues of the active site, (ΔG~residue)~ calculations were performed using the MMGBSA method. The total energy decomposition values associated with ligand binding is represented in [Fig. 9](#fig9){ref-type="fig"} . We highlighted here only the significant energy contributing residues in ligand binding. Briefly, the obtained results revealed that residues, including Asp164, Met208, Pro247, Pro248, Tyr264, and Thr301 located in the active site of SARS-COV-2 PL^pro^ were found important for interaction with ADM_13083841, LMG_15521745, and SYN_15517940. Among these, the residual decomposition analysis revealed the favorable contribution (\<-1.7 kcal/mol) of Asp164, which exhibited ΔG~residue~ of -1.92, -1.86, and -1.74 kcal/mol, Tyr264 which exhibited ΔG~residue~ of -2.14, -2.08, and -2.81 kcal/mol with ADM_13083841, LMG_1552174 and SYN_15517940, respectively. Moreover, Tyr264 was also found interacting through H-bonds in all three complexes ([Fig. 5](#fig5){ref-type="fig"}).Fig. 9Per-residue decomposition analysis using MM-GBSA methods and highly interacting binding site residues are displayed together with ΔG~residue~ derived from last 20 ns of MD simulations.Fig. 9

In comparison, the ΔG~residue~ values of co-crystallized GRL‐0667S showed a relatively similar trend. Hence, ΔG~residue~ energies of highly interacting residues suggested that the molecular structures of all three compounds fitted well inside the active-site of SARS-COV-2 PL^pro^. Moreover, the obtained results after residual decomposition analysis were in accordance with the complex stability analysis through MD simulation, where the stable RMSD was achieved due to these pairwise interactions throughout the simulation period. Hence, hypothesized that these critically important active site residues might be crucial in inhibitor recognition for the development of SARS-COV-2 PL^pro^ inhibitors and could lead to further optimization of these compounds.

3.7. Molecular docking of screened hits with SARS-CoV and MERS-CoV PL^pros^ {#sec3.7}
---------------------------------------------------------------------------

Disulfiram is an FDA approved drug used to treat chronic alcoholism. Previous research reported that disulfiram can inhibit SARS-CoV and MERS-CoV PL^pros^ as allosteric, competitive or mixed inhibitor \[[@bib101]\]. Disulfiram has also been proposed for the treatment of SARS-CoV-2 \[[@bib102], [@bib103], [@bib104]\]. Similarly, previous studies reported that lopinavir showed promising results against MERS-CoV \[[@bib105], [@bib106], [@bib107], [@bib108]\] and SARS-CoV \[[@bib109], [@bib110], [@bib111]\], and currently it is under clinical trials for COVID-19 treatment \[[@bib11], [@bib112], [@bib113], [@bib114]\]. Lopinavir is an FDA approved serine protease inhibitor used to treat HIV-1 infection \[[@bib115]\]. Therefore, to test the hypothesis and validate the possibility of pan-PL^pro^ based broad-spectrum inhibitors, next we determined the ability of the selected compounds to bind to the SARS-CoV and MERS-CoV PL^pros^, by the validated flexible docking approach into the same target site. Interestingly, these compounds showed high binding affinity toward SARS-CoV PL^pro^ with binding energy scores ranged from -8.7 to -7.9 kcal/mol ([Fig. 10](#fig10){ref-type="fig"} ). However, the binding energy scores of these compounds were low in the case of MERS-CoV, ranged from -5.9 to -6.7 kcal/mol, indicating that their activity toward SARS-CoV might be greater than the activity against MERS-CoV ([Fig.11](#fig11){ref-type="fig"} ). This could be because of the structural difference of MERS-CoV blocking loop 2 (BL2) \[[@bib116]\].Fig. 10Binding modes and molecular interactions of screened compounds with SARS-CoV PL^pro^ (PDB: 3MJ5). (**A**) Surface representation of the binding mode of co-crystalized GRL‐0667S (cyan), docked GRL‐0667S (orange), ADM_13083841 (white), LMG_1552174 (pink) and SYN_15517940 (green) to SARS-CoV PL^pro^ (yellow). (**B**) The mechanism of molecular interactions of compounds to SARS-CoV PL^pro^. (**a**) Close view to the binding mode of co-crystalized GRL‐0667S (cyan) and docked GRL‐0667S (orange) to SARS-CoV PL^pro^ (**b**) ADM_13083841 (white), (**c**) LMG_1552174 (pink) and (**d**) SYN_15517940 (green) to SARS-CoV-2 PL^pro^.Fig. 10Fig. 11Binding modes and molecular interactions of screened compounds with MERS-CoV PL^pro^ (PDB: 4R3D). (**A**) Surface representation of the binding mode of docked GRL‐0667S (orange), ADM_13083841 (white), LMG_1552174 (pink) and SYN_15517940 (yellow) to MERS-CoV PL^pro^ (pink). (**B**) The mechanism of molecular interactions of compounds to MERS-CoV PL^pro^ (**a**) Close view to the binding mode of docked GRL‐0667S (orange) to MERS-CoV PL^pro^ (**b**) ADM_13083841 (white), (**c**) LMG_1552174 (pink) and (**d**) SYN_15517940 (green) to SARS-CoV-2 PL^pro^.Fig. 11

Our effort to target the deadliest human CoVs (SARS-CoV, SARS-CoV-2 and MERS-CoV) PL^pro^ concurrently by investigating their conservation (structural and functional) produced significant results. The present study recognized three small-molecule protease inhibitors with great capability of drug leads, capable of inhibiting PL^pro^ of SARS-CoV-2. These set of compounds could function as broad-spectrum pan-PL^pro^ inhibitors against deadly human CoVs infections. This is critically important against constantly evolving CoVs. The benefits of treatment strategies involving pan-inhibitors have already been reported in the case of Dengue virus \[[@bib28], [@bib117]\], HCV \[[@bib118], [@bib119], [@bib120], [@bib121]\], and HIV \[[@bib122]\]. The screened inhibitors in the present study may lead towards a medicinal solution against the variety of constantly evolving CoVs by effectively targeting/hindering the proteolytic role of their PL^pro^. Therefore, our findings warrant further experimental work on screened pan-PL^pro^ inhibitors for further drug optimization.

4. Conclusions {#sec4}
==============

This comprehensive study offers an integrated computational approach towards the discovery of three novel hit compounds, screened from a focused library of ∼7000 compounds having a diverse scaffold that could specifically target SARS-COV-2 PL^pro^, which permits in vitro evaluations. These three compounds, ADM_13083841, LMG_1552174, and SYN_15517940, were selected for further computational studies to get a deep insight into their binding mode, mechanism of molecular interaction, and ADMET analysis. The in-depth structural exploitation of key residues of the active site together with the dynamic scaffolds of hit compounds adopted after 50 ns MD simulations offered the way to design broad-spectrum inhibitors against deadly human CoVs. To support, structural/functional conservation of SARS-CoV, MERS-CoV, and SARS-CoV-2 revealed strikingly similar conformations of active site residues. Altogether, the identification of highly contributing residues towards overall ligand binding energy might provide an excellent platform to further enhance the inhibitor recognition potential of SARS-COV-2 PL^pro^. Although the present study lacks *in silico* binding mode validation, the structural evidence obtained from this computational study has surfaced the way in the designing of pan-PL^pro^ based inhibitors as broad-spectrum antiviral agents to combat SARS-CoV-2 and other pathogenic human coronaviruses.
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[^2]: Note: ΔG~bind~ is the sum of molecular mechanics energy (ΔE~MM~) which is the gas term, and solvation free energy (ΔG~sol~). Both ΔE~MM~ and ΔG~sol~ are further divided into internal energy (ΔE~int~), electrostatic energy (ΔE~ele~), and van der Waals (ΔE~vdw~) energy, and polar (ΔG~p~) and non-polar (ΔG~np~) contributions to the solvation free energy. Solvation term were included from both MM/PBSA and MM/GBSA methods. These calculations were executed with the incorporation of entropic term (TΔS) by the following equation: ΔG~bind\ (MM-PB(GB)SA)~ = ΔE~MM~ + ΔG~sol~ -- TΔS.
